BACKGROUND: Studies suggest that vitamin D status may be associated with prostate cancer risk although the direction and strength of this association differs between experimental and observational studies. Genome-wide association studies have identified genetic variants associated with 25-hydroxyvitamin D [25(OH)D] status. We examined prostate cancer risk in relation to single-nucleotide polymorphisms (SNP) in four genes shown to predict circulating levels of 25(OH)D. METHODS: SNP markers localized to each of four genes (GC, CYP24A1, CYP2R1, and DHCR7) previously associated with 25(OH)D were genotyped in 10,018 cases and 11,052 controls from the National Cancer Institute (NCI) Breast and Prostate Cancer Cohort Consortium. Logistic regression was used to estimate the individual and cumulative association between genetic variants and risk of overall and aggressive prostate cancer. RESULTS: We observed a decreased risk of aggressive prostate cancer among men with the allele in rs6013897 near CYP24A1 associated with lower serum 25(OH)D [per A allele, OR, 0.86; 95% confidence interval (CI), 0.80-0.93; Ptrend = 0.0002) but an increased risk for nonaggressive disease (per A allele: OR, 1.10; 95% CI, 1.04-1.17; Ptrend = 0.002). Examination of a polygenic score of the four SNPs revealed statistically significantly lower risk of aggressive prostate cancer among men with a greater number of low vitamin D alleles (OR for 6-8 vs. 0-1 alleles, 0.66; 95% CI, 0.44-0.98; Ptrend = 0.003). CONCLUSIONS: In this large, pooled analysis, genetic variants related to lower 25(OH)D levels were associated with a decreased risk of aggressive prostate cancer. IMPACT: Our genetic findings do not support a protective association between loci known to influence vitamin D levels and prostate cancer risk.
BACKGROUND: Studies suggest that vitamin D status may be associated with prostate cancer risk although the direction and strength of this association differs between experimental and observational studies. Genome-wide association studies have identified genetic variants associated with 25-hydroxyvitamin D [25(OH)D] status. We examined prostate cancer risk in relation to single-nucleotide polymorphisms (SNP) in four genes shown to predict circulating levels of 25(OH)D. METHODS: SNP markers localized to each of four genes (GC, CYP24A1, CYP2R1, and DHCR7) previously associated with 25(OH)D were genotyped in 10,018 cases and 11,052 controls from the National Cancer Institute (NCI) Breast and Prostate Cancer Cohort Consortium. Logistic regression was used to estimate the individual and cumulative association between genetic variants and risk of overall and aggressive prostate cancer. RESULTS: We observed a decreased risk of aggressive prostate cancer among men with the allele in rs6013897 near CYP24A1 associated with lower serum 25(OH)D [per A allele, OR, 0.86; 95% confidence interval (CI), 0.80-0.93; Ptrend = 0.0002) but an increased risk for nonaggressive disease (per A allele: OR, 1.10; 95% CI, 1.04-1.17; Ptrend = 0.002). Examination of a polygenic score of the four SNPs revealed statistically significantly lower risk of aggressive prostate cancer among men with a greater number of low vitamin D alleles (OR for 6-8 vs. 0-1 alleles, 0.66; 95% CI, 0.44-0.98; Ptrend = 0.003). CONCLUSIONS: In this large, pooled analysis, genetic variants related to lower 25(OH)D levels were associated with a decreased risk of aggressive prostate cancer. IMPACT: Our genetic findings do not support a protective association between loci known to influence vitamin D levels and prostate cancer risk.
Authors: La Creis R Kidd; Dina N Paltoo; Songping Wang; Weidong Chen; Folasade Akereyeni; William Isaacs; Chiledum Ahaghotu; Rick Kittles Journal: Prostate Date: 2005-08-01 Impact factor: 4.104
Authors: D J Hunter; E Riboli; C A Haiman; D Albanes; D Altshuler; S J Chanock; R B Haynes; B E Henderson; R Kaaks; D O Stram; G Thomas; M J Thun; H Blanché; J E Buring; N P Burtt; E E Calle; H Cann; F Canzian; Y C Chen; G A Colditz; D G Cox; A M Dunning; H S Feigelson; M L Freedman; J M Gaziano; E Giovannucci; S E Hankinson; J N Hirschhorn; R N Hoover; T Key; L N Kolonel; P Kraft; L Le Marchand; S Liu; J Ma; S Melnick; P Pharaoh; M C Pike; C Rodriguez; V W Setiawan; M J Stampfer; E Trapido; R Travis; J Virtamo; S Wacholder; W C Willett Journal: Nat Rev Cancer Date: 2005-12 Impact factor: 60.716
Authors: Pentti Tuohimaa; Leena Tenkanen; Merja Ahonen; Sonja Lumme; Egil Jellum; Göran Hallmans; Pär Stattin; Sverre Harvei; Timo Hakulinen; Tapio Luostarinen; Joakim Dillner; Matti Lehtinen; Matti Hakama Journal: Int J Cancer Date: 2004-01-01 Impact factor: 7.396
Authors: Linda T Hiraki; Jacqueline M Major; Constance Chen; Marilyn C Cornelis; David J Hunter; Eric B Rimm; Kelly C Simon; Stephanie J Weinstein; Mark P Purdue; Kai Yu; Demetrius Albanes; Peter Kraft Journal: Genet Epidemiol Date: 2012-11-07 Impact factor: 2.135
Authors: Kathleen Torkko; Cathee Till; Catherine M Tangen; Phyllis J Goodman; Xiaoling Song; Jeannette M Schenk; M Scott Lucia; Ulrike Peters; Adrie van Bokhoven; Ian M Thompson; Marian L Neuhouser Journal: Cancer Prev Res (Phila) Date: 2020-02-26
Authors: Irene M Shui; Alison M Mondul; Sara Lindström; Konstantinos K Tsilidis; Ruth C Travis; Travis Gerke; Demetrius Albanes; Lorelei A Mucci; Edward Giovannucci; Peter Kraft Journal: Cancer Date: 2015-03-02 Impact factor: 6.860
Authors: Linda T Hiraki; Conghui Qu; Carolyn M Hutter; John A Baron; Sonja I Berndt; Stéphane Bézieau; Hermann Brenner; Bette J Caan; Graham Casey; Jenny Chang-Claude; Stephen J Chanock; David V Conti; David Duggan; Charles S Fuchs; Steven Gallinger; Edward L Giovannucci; Tabitha A Harrison; Richard B Hayes; Aditi Hazra; Brian Henderson; Michael Hoffmeister; John L Hopper; Thomas J Hudson; Mark A Jenkins; Sébastien Küry; Loic Le Marchand; Mathieu Lemire; Jing Ma; Joann E Manson; Hongmei Nan; Polly A Newcomb; Kimmie Ng; John D Potter; Robert E Schoen; Fredrick R Schumacher; Daniela Seminara; Martha L Slattery; Jean Wactawski-Wende; Emily White; Kana Wu; Brent W Zanke; Peter Kraft; Ulrike Peters; Andrew T Chan Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-08-27 Impact factor: 4.254
Authors: Xia Jiang; Niki L Dimou; Kawthar Al-Dabhani; Sarah J Lewis; Richard M Martin; Philip C Haycock; Marc J Gunter; Timothy J Key; Rosalind A Eeles; Kenneth Muir; David Neal; Graham G Giles; Edward L Giovannucci; Meir Stampfer; Brandon L Pierce; Joellen M Schildkraut; Shaneda Warren Andersen; Deborah Thompson; Wei Zheng; Peter Kraft; Konstantinos K Tsilidis Journal: Int J Epidemiol Date: 2019-10-01 Impact factor: 7.196
Authors: David Feldman; Aruna V Krishnan; Srilatha Swami; Edward Giovannucci; Brian J Feldman Journal: Nat Rev Cancer Date: 2014-04-04 Impact factor: 60.716
Authors: Elizabeth L Barry; Judy R Rees; Janet L Peacock; Leila A Mott; Christopher I Amos; Roberd M Bostick; Jane C Figueiredo; Dennis J Ahnen; Robert S Bresalier; Carol A Burke; John A Baron Journal: J Clin Endocrinol Metab Date: 2014-07-29 Impact factor: 5.958